Clinical Trial: Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07427394) titled 'Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer' on Feb. 16.

Brief Summary: A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Study Start Date: April 10

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: Camizestrant

Camizestrant will be administered orally.

DRUG: Atirmociclib

Atirmociclib...